Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7838)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Mar 14, 2023 (publication date) through May 30, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1551-1568 [PMID: 36970588 DOI: 10.3748/wjg.v29.i10.1551] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i10/1551.htm |
| Number | Citing Articles |
| 1 |
Qianming Kang, Luying He, Yang Zhang, Zhangfeng Zhong, Wen Tan. Immune-inflammatory modulation by natural products derived from edible and medicinal herbs used in Chinese classical prescriptions. Phytomedicine 2024; 130: 155684 doi: 10.1016/j.phymed.2024.155684
|
| 2 |
Sewoon Chun, Erin M Coyne, Jeffrey Meyer, Won Jin Ho. Durable Response to Combined Nivolumab, Lenvatinib, and Radiation Therapy Against Oligometastatic Hepatocellular Carcinoma. Cureus 2024; doi: 10.7759/cureus.73434
|
| 3 |
Zakria A Abdulal, Mohammed Y Altahhan, Abdulrahman F Qindil, Aseel M Al-Juhani, Manahel A Alatawi, Hanan M Hassan, Mohammed MH Al-Gayyar. Ferulic acid inhibits tumor proliferation and attenuates inflammation of hepatic tissues in experimentally induced HCC in rats. Journal of Investigative Medicine 2024; 72(8): 900 doi: 10.1177/10815589241270489
|
| 4 |
YU ZHANG, CHUNTING WANG, QIU LI, HAIYING PANG, FENGBO WU, GU HE, NAN ZHANG, PENG ZHANG. EMP2 promotes hepatocellular carcinoma proliferation and invasion by activating cellular autophagy. Oncology Research 2025; 33(2): 443 doi: 10.32604/or.2024.043948
|
| 5 |
Cong-Cong Wang, Cai-Yan Yu, Jing Zhang, Rui Wang, Xiang-Shuo Kong. A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022). Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1159286
|
| 6 |
Mohan Huang, Tian Lan, Xinyue Chen, Rong Chen, Xin Ding, William Chi-Shing Tai, Sze Chuen-Cesar Wong, Lawrence Wing-Chi Chan. Functional Role of NOXA in Hypoxia-Mediated PD-L1 Inhibitor Response in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2025; 26(10): 4766 doi: 10.3390/ijms26104766
|
| 7 |
Sumit Roy, Vancha Harish, Sharfuddin Mohd, Sachin Kumar Singh. Breaking Down the Arsenal: Recent Progress in the Nanotherapeutic Strategies for Hepatocellular Carcinoma Treatment. Advanced Therapeutics 2024; doi: 10.1002/adtp.202400126
|
| 8 |
Dujinthan Jayabalan, Sugam Dhakal, Aarohanan Raguragavan, Akshat Saxena, Gary P. Jeffrey, Luis Calzadilla-Bertot, Leon A. Adams, Michael C. Wallace, Dirk Uhlmann. Hepatocellular Carcinoma and Health‐Related Quality of Life: A Systematic Review of Outcomes From Systemic Therapies. International Journal of Hepatology 2025; 2025(1) doi: 10.1155/ijh/1083642
|
| 9 |
David E. Kaplan, Ruoding Tan, Cheryl Xiang, Fan Mu, Sairy Hernandez, Sarika Ogale, Jiayang Li, Yilu Lin, Lizheng Shi, Amit G. Singal. Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database. Cancers 2024; 16(20): 3508 doi: 10.3390/cancers16203508
|
| 10 |
Tania Payo‐Serafín, Carolina Méndez‐Blanco, Paula Fernández‐Palanca, Jennifer Martínez‐Geijo, María Reviejo, Juan José Ortiz‐de‐Urbina, Javier González‐Gallego, Jose J. G. Marin, José L. Mauriz, Beatriz San‐Miguel. Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Clinical Pharmacology & Therapeutics 2024; 116(2): 328 doi: 10.1002/cpt.3312
|
| 11 |
Xuekai Hu, Jiayun Wei, Pinyan Liu, Qiuxia Zheng, Yue Zhang, Qichen Zhang, Jia Yao, Jingman Ni. Organoid as a promising tool for primary liver cancer research: a comprehensive review. Cell & Bioscience 2024; 14(1) doi: 10.1186/s13578-024-01287-5
|
| 12 |
Shuyue Xiao, Xiaohui Huang, Shuer Liu, Di Jin, Zheng Liu. Alterations of Nutrient Elements in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab. Nutrition and Cancer 2025; 77(2): 244 doi: 10.1080/01635581.2024.2415136
|
| 13 |
Mohammad SS Naviwala, Daania Shoaib, Waqas A Khan, Adeeba Zaki. Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report. Euroasian journal of hepato-gastroenterology 2024; 14(2): 246 doi: 10.5005/jp-journals-10018-1455
|
| 14 |
Chen Huang, Yangqian Li, Fengmei Zhang, Chenliang Zhang, Zhenyu Ding. Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma. International Journal of Surgery 2025; 111(4): 2990 doi: 10.1097/JS9.0000000000002294
|
| 15 |
Megan E. Bannister, Devnandan A. Chatterjee, Shishir Shetty, Daniel A. Patten. The Role of Macrophages in Hepatocellular Carcinoma and Their Therapeutic Potential. International Journal of Molecular Sciences 2024; 25(23): 13167 doi: 10.3390/ijms252313167
|
| 16 |
Nojan Bajestani, Gavin Wu, Ahmed Hussein, Mina S. Makary. Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma. Biomedicines 2024; 12(7): 1432 doi: 10.3390/biomedicines12071432
|
| 17 |
Claudia R. Silver, Cynthia De la Garza-Ramos, John A. Stauffer, Umair Majeed, Jianfeng Wang, Beau B. Toskich. Ipilimumab and nivolumab plus radioembolization as salvage therapy for atezolizumab and bevacizumab refractory hepatocellular carcinoma resulting in complete pathologic response. Radiology Case Reports 2024; 19(11): 5024 doi: 10.1016/j.radcr.2024.07.157
|
| 18 |
Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Yu Noda, Etsuko Moriyama, Hiroyuki Suzuki, Hironori Koga, Ryoko Kuromatsu, Takumi Kawaguchi. Dose-Reduction of Bevacizumab in Atezolizumab plus Bevacizumab Therapy Extends Treatment duration with Disease Control in Patients with Hepatocellular Carcinoma. Oncology 2024; : 1 doi: 10.1159/000541082
|
| 19 |
Shahad A Alshehri, Wasayf A Almarwani, Ajwan Z Albalawi, Shekha M Al-atwi, Khulud K Aljohani, Amjad A Alanazi, Mohamed A Ebrahim, Hanan M Hassan, Mohammed M Al-Gayyar. Role of Arctiin in Fibrosis and Apoptosis in Experimentally Induced Hepatocellular Carcinoma in Rats. Cureus 2024; doi: 10.7759/cureus.51997
|
| 20 |
Xu‐Yan Wang, Yuan Liao, Rui‐Qi Wang, Yi‐Tong Lu, Ying‐Zhe Wang, Yu‐Qi Xin, Dong‐Ming Kuang, Xiang‐Ming Lao, Junying Xu, Zhi‐Ling Zhou, Kunhua Hu. Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil‐Mediated Lung Metastasis in Hepatocellular Carcinoma. Advanced Science 2025; 12(13) doi: 10.1002/advs.202413682
|
| 21 |
Shui Liu, Qiao Li, Yongzhi Li, Jiyao Sheng. Editorial: Advances in chemotherapy-resistant hepatocellular carcinoma. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1325304
|
| 22 |
Junfeng Bu, Zihan Li, Die Hu, Ling Lan, Jiwei Huang, Xin Wang, Qiu Li, Jin Zhou, Yong Zeng. Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study. Frontiers in Oncology 2025; 15 doi: 10.3389/fonc.2025.1554711
|
| 23 |
Yitao Zheng, Yanjun Xiang, Hongqi Shi, Zhuoqun Lin, Shuqun Cheng, Jiuting Zhu. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate‐stage Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma 2024; : 1079 doi: 10.2147/JHC.S461630
|
| 24 |
Yang-Bo Zhu, Jia-Yi Qin, Ting-Ting Zhang, Wen-Jin Zhang, Qi Ling. Reassessment of palliative surgery in conversion therapy of previously unresectable hepatocellular carcinoma: Two case reports and review of literature. World Journal of Gastrointestinal Surgery 2024; 16(10): 3312-3320 doi: 10.4240/wjgs.v16.i10.3312
|
| 25 |
Hongfu Cai, Jingwen Lin, Huide Zhu, Zhiwei Zheng. Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis. BMJ Open 2024; 14(12): e079603 doi: 10.1136/bmjopen-2023-079603
|
| 26 |
Manisri Porukala, P. K. Vinod, Amy McCart Reed. Gene expression signatures of stepwise progression of Hepatocellular Carcinoma. PLOS ONE 2023; 18(12): e0296454 doi: 10.1371/journal.pone.0296454
|
| 27 |
Priyadarshini Mohapatra, Natarajan Chandrasekaran.
In vitro β-catenin attenuation by a mefloquine-loaded core–shell nano emulsion strategy to suppress liver cancer cells. Nanoscale Advances 2025; 7(3): 748 doi: 10.1039/D4NA00547C
|
| 28 |
Ryo Yano, Masashi Hirooka, Yoshiko Nakamura, Yusuke Imai, Yohei Koizumi, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa. A case of hepatocellular carcinoma with pseudoaneurysm formation upon lenvatinib administration. Clinical Journal of Gastroenterology 2024; 17(2): 319 doi: 10.1007/s12328-023-01914-7
|